[HTML][HTML] Macromolecular drug carriers for targeted glioblastoma therapy: preclinical studies, challenges, and future perspectives

D Raucher, S Dragojevic, J Ryu - Frontiers in oncology, 2018 - frontiersin.org
Glioblastoma, the most common, aggressive brain tumor, ranks among the least curable
cancers—owing to its strong tendency for intracranial dissemination, high proliferation …

EGFR inhibition by curcumin in cancer cells: a dual mode of action

M Starok, P Preira, M Vayssade, K Haupt… - …, 2015 - ACS Publications
Epidermal Growth Factor Receptor (EGFR) is an important target of anticancer therapy.
Nowadays, the search for new molecules inhibiting this receptor is turning toward natural …

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

H Li, K Takayama, S Wang, Y Shiraishi… - Cancer chemotherapy …, 2014 - Springer
Purpose Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
(TKI), and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, are …

Adnectin-based design of chimeric antigen receptor for T cell engineering

X Han, GE Cinay, Y Zhao, Y Guo, X Zhang, P Wang - Molecular Therapy, 2017 - cell.com
Although chimeric antigen receptor (CAR)-engineered T cell therapy has achieved
encouraging clinical trial results for treating hematological cancers, further optimization can …

Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells

RSM Ismail, SM Abou-Seri, WM Eldehna… - European Journal of …, 2018 - Elsevier
Epidermal growth factor receptor (EGFR) signaling pathway has been previously
investigated for its significant role in the progression of different types of malignant tumors …

Designed DNA nanostructure grafted with erlotinib for non-small-cell lung cancer therapy

Y Wang, J Cheng, D Zhao, Y Liu, T Luo, YF Zhong… - Nanoscale, 2020 - pubs.rsc.org
Chemotherapy for non-small-cell lung cancer (NSCLC) treatment has been employed over
the past 20 years. However, poor water-solubility, low bioavailability and less drug …

Synthesis and Biological Evaluation of Benzo [d] thiazolyl‐Sulfonyl‐Benzo [4, 5] isothiazolo [2, 3‐c][1, 2, 3] triazole Derivatives as EGFR Targeting Anticancer Agents

E Ramya Sucharitha, S Kumar Nukala… - …, 2023 - Wiley Online Library
A one‐step procedure for the synthesis of new fused Benzo [d] thiazolo‐1, 2, 3‐triazoles (3 a–
3 h and 4 a–4 h) in good yields using sulfonylazides (2) and iodoalkyne (1) through from the …

Immunomodulatory therapy in head and neck squamous cell carcinoma: recent advances and clinical prospects

A Khadela, Y Shah, P Mistry… - Technology in Cancer …, 2023 - journals.sagepub.com
The immune system plays a significant role in the development, invasion, progression, and
metastasis of head and neck cancer. Over the last decade, the emergence of …

Ligand-based pharmacophore modeling, molecular docking, and molecular dynamic studies of dual tyrosine kinase inhibitor of EGFR and VEGFR2

F Sangande, E Julianti, DH Tjahjono - International journal of molecular …, 2020 - mdpi.com
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2
(VEGFR2) play an important role in cancer growth. Both of them have close relationships …

Fluorescent kinase inhibitors as probes in cancer

SM Usama, B Zhao, K Burgess - Chemical Society Reviews, 2021 - pubs.rsc.org
Fluorescent dyes attached to kinase inhibitors (KIs) can be used to probe kinases in vitro, in
cells, and in vivo. Ideal characteristics of the dyes vary with their intended applications …